Patents by Inventor Steven M. Ruben

Steven M. Ruben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Albumin Fusion Proteins
    Publication number: 20080146503
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Application
    Filed: July 2, 2007
    Publication date: June 19, 2008
    Applicants: Human Genome Sciences, Inc., Delta Biotechnology Limited
    Inventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
  • Antibodies to HBIMF63 polypeptide
    Patent number: 7381800
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: June 3, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Yanggu Shi, Paul E. Young, Reinhard Ebner, Daniel R. Soppet, Steven M. Ruben
  • Antibodies that specifically bind to chemokine beta-4
    Patent number: 7375192
    Abstract: The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune diseases, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-B4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: May 20, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Treatment of Sjogren's syndrome by administration of TR18 polypeptides
    Patent number: 7371388
    Abstract: The present invention relates to TR18 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR18 protein. TR18 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR18 activity. The invention further relates to methods of treating, preventing, prognosing, or diagnosing an autoimmune disease or condition associated with an autoimmune disease, comprising administering to a patient an effective amount of polypeptides of the invention.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: May 13, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Kevin P. Baker
  • Human secreted proteins
    Patent number: 7368531
    Abstract: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding the polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to the human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing the polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: May 6, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Peptidoglycan recognition proteins
    Patent number: 7368244
    Abstract: The present invention related to three novel peptidoglican recognition binding protein expressed by keratinocytes, wound-healing tissues and chondrosarcoma tissue. More specifically, isolated nucleic acid molecules are provided encoding human peptidoglycan recognition protein-related proteins, referred to herein as PGRP-K (Keratinocytes), PGRP-W (Wound-healing), and PGRP-C (Chondrosarcoma) of FIGS. 1A-B, FIGS. 2A-C, and FIG. 3, respectively, each having homology to both human peptidoglycan recognition protein (PGRP) as well as murine Tag-7. PGRP-K, PGRP-W, and PGRP-C polypeptides are also provided. Further provided are vectors, host cells and recombinant methods for producing the same. The invention also relates to both the inhibition and enhancement of activities of PGRP-K, PGRP-W, and PGRP-c polypeptides and diagnostic methods for detecting PGRP-K, PGRP-W, and PGRP-C gene expression.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: May 6, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Paul E. Young, Steven M. Ruben, Craig A. Rosen, Henrik S. Olsen
  • HADDE71 polypeptides
    Patent number: 7368527
    Abstract: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: May 6, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1)
    Patent number: 7364865
    Abstract: There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine ?8 (CK?8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-? and chemokine ?1(CK?1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: April 29, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Brent L. Kreider, Jun Zhang, Michael Antonaccio, Donna Mendrick, Pablo Jimenez, Vikram Patel, Craig A. Rosen, Mark D. Adams, Haodong Li, Steven M. Ruben
  • Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
    Patent number: 7361341
    Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: April 22, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Theodora W. Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
  • Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
    Patent number: 7348003
    Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: March 25, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Theodora W. Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
  • Heregulin-like factor
    Patent number: 7335738
    Abstract: The present invention relates to a novel HLF protein which is a member of the heregulin family. In particular, isolated nucleic acid molecules are provided encoding the human HLF protein. HLF polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of HLF activity. Also provided are diagnostic methods for detecting disorders of the regulation of cell growth and therapeutic methods for treating disorders of the regulation of cell growth.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: February 26, 2008
    Assignees: Human Genome Sciences, Inc., Georgetown University Medical Center
    Inventors: Paul E. Young, Richter C. King, Mia Hijazi, Steven M. Ruben
  • Antibodies to Chemokine Alpha-5
    Patent number: 7320869
    Abstract: The present invention relates to a novel CK?-5 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK?-5 protein. CK?-5 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Antibodies and fragments thereof that specifically bind to CK?-5 polypeptides are also disclosed, as are compositions and methods for making such antibodies. The invention further relates to screening methods for identifying agonists and antagonists of CK?-5 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: January 22, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ying-Fei Wei, Yi Li, Jian Ni, Craig A. Rosen, Steven M. Ruben
  • Polynucleotides encoding dendritic enriched secreted lymphocyte activation molecule
    Patent number: 7312051
    Abstract: The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: December 25, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Paul E. Young
  • Interleukin 17 Receptor-Like Protein
    Publication number: 20070269439
    Abstract: The present invention relates to a novel IL17RLP protein which is a member of the interleukin (IL)-17 receptor family. In particular, isolated nucleic acid molecules are provided encoding the human IL17RLP protein. IL17RLP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of IL17RLP activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating, diagnosing, detecting, and/or preventing immune system-related disorders.
    Type: Application
    Filed: December 6, 2006
    Publication date: November 22, 2007
    Applicant: Human Genome Sciences, Inc.
    Inventors: Yanggu Shi, Steven M. Ruben
  • Tumor necrosis factor receptors 6? & 6?
    Patent number: 7285267
    Abstract: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6? & -6? proteins. TNFR-6? & -6? polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6? & -6? activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: October 23, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Jian Ni, Ping Feng
  • Antibodies to human Ependymin
    Patent number: 7252956
    Abstract: The present invention relates to a novel human Ependymin protein which is a member of the ependymin family. In particular, isolated nucleic acid molecules are provided encoding the human Ependymin protein. Ependymin polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Ependymin activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: August 7, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reinhard Ebner, Steven M. Ruben
  • Antibodies to HHPEN62 polypeptide
    Patent number: 7247442
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: July 24, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Kimberly A. Florence, Jian Ni, Craig A. Rosen, Kenneth C. Carter, Paul A. Moore, Henrik S. Olsen, Yanggu Shi, Paul E. Young, Ying-Fei Wei, Laurie A. Brewer, Daniel R. Soppet, David W. LaFleur, Gregory A. Endress, Reinhard Ebner, Charles E. Birse
  • Albumin fusion proteins
    Patent number: 7238667
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: July 3, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
  • Keratinocyte growth factor-2 polynucleotides
    Patent number: 7232667
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: June 19, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Joachim R. Gruber, D. Roxanne Duan, Mark A. Rampy, Donna Mendrick, Jun Zhang, Jian Ni, Paul A. Moore, Timothy A. Coleman, Patrick J. Dillon, Reiner L. Gentz, Pablo Jimenez
  • Use of vascular endothelial growth factor to treat photoreceptor cells
    Patent number: 7223724
    Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: May 29, 2007
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ralph Alderson, Robert Melder, Viktor Roschke, Steven M. Ruben, Craig A. Rosen